Tag Archives: pan-genotypic

After Harvoni: What’s Still Left to Improve (Besides the Price Tag)?

Posted on by — No Comments ↓

SVR rates in recent DAA combination trials are really impressive.  Hardly a month goes by without yet another trial showing excellent efficacy in populations so far considered ‘difficult to treat’, like cirrhotics or post-liver transplant patients on immunosuppressive therapies.  This Continue reading After Harvoni: What’s Still Left to Improve (Besides the Price Tag)?→

Snapshot: HCV Drugs in Development

Posted on by — No Comments ↓

It’s becoming a daunting task to follow the field given the rapid-fire release of study results and the many recent submissions of new direct-acting antiviral (DAA) drugs. All will be given as cocktails, with or without interferon or ribavirin, and Continue reading Snapshot: HCV Drugs in Development→